Premier Research

CJC-1295 NO DAC + IPAM 5/5MG

CJC-1295 NO DAC + IPAM 5/5MG

$75.00

CJC-1295 NO DAC + Ipamorelin CJC-1295 NO DAC + Ipamorelin blend is a research peptide combination consisting of CJC-1295 without DAC (a short-acting analog of growth hormone-releasing hormone) and Ipamorelin (a selective ghrelin receptor agonist). Preclinical studies in animal models indicate that CJC-1295 NO DAC stimulates pulsatile GH release, while Ipamorelin promotes GH secretion with…

24 in stock

Category:
Tags: , ,

CJC-1295 NO DAC + Ipamorelin

CJC-1295 NO DAC + Ipamorelin blend is a research peptide combination consisting of CJC-1295 without DAC (a short-acting analog of growth hormone-releasing hormone) and Ipamorelin (a selective ghrelin receptor agonist). Preclinical studies in animal models indicate that CJC-1295 NO DAC stimulates pulsatile GH release, while Ipamorelin promotes GH secretion with minimal impact on cortisol or prolactin. When studied together, these peptides may exhibit synergistic effects on sustained yet natural-like GH pulses.[1][2]

Key Research Areas

  • Growth Hormone Pulsatile Secretion – In rodent and porcine models, CJC-1295 NO DAC has been shown to enhance GH pulses, and Ipamorelin selectively stimulates GH release without significant elevation of other hormones; the combination supports amplified yet physiological GH patterns.[3][4]
  • Metabolic & Body Composition Effects – Preclinical research demonstrates increased lipolysis, improved nitrogen retention, and potential lean mass maintenance in models of GH axis activation.[5][6]
  • Recovery & Tissue Support Pathways – Studies suggest the blend may promote protein synthesis, collagen production, and recovery processes through elevated GH/IGF-1 signaling in muscle and connective tissue models.[7][8]

Product Specifications

CAS Number CJC-1295 NO DAC: 863288-34-0 (base sequence) / Ipamorelin: 170851-70-4
Molecular Formula Blend (CJC-1295 NO DAC: C152H252N44O42 / Ipamorelin: C38H49N9O5)
Molar Mass Blend (CJC-1295 NO DAC: 3367.90 g/mol / Ipamorelin: 711.85 g/mol)
Sequence CJC-1295 NO DAC: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Asp-Gly-Glu-Lys
Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2
Synonyms CJC-1295 no DAC + Ipamorelin Blend, Modified GRF (1-29) + Ipamorelin, GH Pulse Blend
Purity ≥99% (HPLC)
Form Lyophilized powder
Storage −20°C (long-term), 2–8°C (reconstituted)
Solubility Bacteriostatic water or sterile saline for reconstitution

References

  1. 1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed
  2. 2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed
  3. 3. Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006. PubMed
  4. 4. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone secretagogue, in healthy volunteers. Pharm Res. 1999. PubMed
  5. 5. Veldhuis JD, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. Growth Horm IGF Res. 2010. PubMed
  6. 6. Sigalos JT, et al. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018. PubMed
  7. 7. Andersen PH, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Regul. 1995. PubMed
  8. 8. Murphy WJ, et al. Growth hormone and the immune system. Endocr Rev. 1996. PubMed
All products offered by Premier Research are intended for laboratory research use only. These materials are not for human or veterinary consumption, medical use, diagnostic procedures, or therapeutic applications. Statements on this website are for informational and educational purposes only and have not been evaluated by the U.S. Food and Drug Administration (FDA). By accessing this site, you confirm that you are a qualified researcher or institution representative and agree to use all materials in accordance with applicable laws, regulations, and safety guidelines.

Related products